The power of informatics and genomic analysis
OpGen harnesses the power of informatics and genomic analysis to detect and track transmissions of antibiotic-resistant microbes. With our large and ever-growing Acuitas Lighthouse database, we analyze pathogens from around the world, and are developing real-time antibiotic guidance for caregivers.

At OpGen, we seek to use precision medicine to manage infectious disease, changing the paradigm of care.

Disruptive Technology
To develop Acuitas Lighthouse, OpGen evaluated more than 250,000 antibiotic resistant isolates from Merck’s SMART surveillance study. We phenotyped approximately 10,000 isolates for antimicrobial susceptibility, testing 29 different antibiotics, and then sequenced the isolates’ DNA to identify 200 unique resistance genes. From that genetic data, OpGen developed statistical models to predict resistance—one of the core features of Acuitas Lighthouse.

OpGen inforgraphic

Our business model

  • Target Pill icon - OpGen
    Validated, Disrup­tive Technology
    Collaborations and partnerships with NY Dept. of Health, Merck, QIAGEN and Thermo Fisher
  • Globe icon
    SIGNIFICANT MARKET OPPORTUNITY
    Working to address a $2B global market in need of novel solutions
  • Bullseye icon
    ADDRESSING MAJOR GLOBAL CRISIS
    Multi-drug resistance causes $20B in excess direct healthcare costs and 700,000 deaths annually
  • Hospital icon
    BUILDING COMMER­CIAL MOMENTUM
    Meeting key commercial milestones including regulatory approvals
  • Team icon
    EXPERIENCED TEAM
    Management has proven track record of value creation for diagnostic, genomic, and pharma companies